ALX Oncology Holdings Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ALX Oncology Holdings Inc. on January 30, 2026. The filing addresses two primary items: a clinical update regarding the Company's investigational CD47-inhibitor evorpacept and preliminary unaudited financial information as of December 31, 2025.
Key Financial Metrics
The filing provides preliminary, unaudited estimates for the Company's liquidity position as of December 31, 2025:
- Cash and Investments: Approximately $48.3 million in cash, cash equivalents, and short-term and long-term investments.
- Revenue, Profit, and Margins: The filing text does not provide a clear value for revenue, net income, operating margins, or cash flow for the period.
- Debt: The filing text does not provide a clear value for outstanding debt obligations.
Note: The Company has not completed its year-end financial close process for the year ended December 31, 2025. These figures are preliminary and subject to change.
Material Changes and Clinical Updates
The Company announced new data from a Phase 1b/2 clinical trial evaluating evorpacept in combination with Jazz Pharmaceuticals' ZIIHERA (zanidatamab-hrii) for heavily pretreated patients with metastatic breast cancer (mBC). Key findings include:
- An exploratory analysis indicates that among patients with confirmed HER2-positive mBC, CD47 expression is predictive of evorpacept activity.
- The data supports the ongoing development of the CD47-inhibitor in combination therapies.
Outlook, Risks, and Management Commentary
Management highlighted that the financial figures disclosed are forward-looking statements based on preliminary estimates. The filing includes a cautionary statement noting that actual results may differ materially due to known and unknown risks. The Company's independent registered public accounting firm has not audited or reviewed these preliminary results and expresses no opinion on them. No specific guidance for future periods was provided in this filing.
Investor Verification Checklist
- Verify the final audited cash and investment balances once the year-end financial close for December 31, 2025, is completed.
- Review the full press release (Exhibit 99.1) for detailed clinical trial data and patient demographics.
- Monitor upcoming filings (10-K or 10-Q) for comprehensive revenue, expense, and debt metrics not included in this 8-K.
- Assess the timeline for the next clinical trial milestones for evorpacept.